$ALNY Phase 3 meets end point; Gets Analysts’ love
Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint.
Gets Analyst love:
| Analyst | Action | Rating | Target |
| Cowen and Company | Reiterates | Outperform | $93.00 -> $117.00 |
| JMP Securities | Raises Target | Outperform | $101.00 -> $128.00 |
| Needham & Company LLC | Raises Target | $85.00 -> $125.00 | |
| Piper Jaffray Companies | Reiterates | Overweight | $110.00 -> $116.00 |
| Stifel Nicolaus | Reiterates | Hold | $56.00 -> $83.00 |
Check out more such briefs in our Daily Pharma Scoop at SeekingAlpha Marketplace.